hotspot -WSS

hotspot

author：knowledge 2025-09-29 01:38:21 - browse：7

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Democrats decry new health bill for going easy on private equity

WSS

'Investigate these claims': UFO transparency at center of House hearing

In Memoriam: Notable people who died in 2023

Why patients can’t get everything they want on drug pricing

Truvian presents data for its desktop blood

Hepatitis C has a cure — but many Americans still lack access to it

New lawsuit accuses health insurer Cigna of denying claims in bulk

focus

hotspot

Wikipedia

Virginia high school admissions case could be legal follow

In age of alternative facts, a scholarly course on calling out crap

Psychedelics group wrestles with new pharma identity

The cancer drug shortage isn’t new — and neither are the solutions

Malaria cases in Florida and Texas: Here’s what you need to know

What it's like to live with paralysis for one psychologist

Sports medicine is finally prioritizing gender equality

How one medical school became remarkably diverse

United colonoscopy coverage change 'may cost lives,' doctors say

A new crop of companies is reshaping the health data economy

entertainment

At least 13 dead in Texas as scorching temps continue

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Trump demands the U.S. pay no more for drugs than other countries … again

A new crop of companies is reshaping the health data economy

CDC Director Mandy Cohen on transparency, trust, and health

Cancer drug shortages should be causing more outrage

entertainment

explore

leisure time

Wikipedia